Chinese Journal of Tissue Engineering Research ›› 2019, Vol. 23 ›› Issue (24): 3875-3881.doi: 10.3969/j.issn.2095-4344.1297

Previous Articles     Next Articles

Correlation between miRNA and pathological development of osteoarthritis

Wang Jicheng1, 2, Yi Zhi1
  

  1. 1Department of Orthopedics, Shaanxi Provincial People’s Hospital, Xi’an 710068, Shaanxi Province, China; 2Xi’an Medical University, Xi’an 710068, Shaanxi Province, China
  • Online:2019-08-28 Published:2019-08-28
  • Contact: Yi Zhi, MD, Professor, Chief physician, Department of Orthopedics, Shaanxi Provincial People’s Hospital, Xi’an 710068, Shaanxi Province, China
  • About author:Wang Jicheng, Master candidate, Department of Orthopedics, Shaanxi Provincial People’s Hospital, Xi’an 710068, Shaanxi Province, China; Xi’an Medical University, Xi’an 710068, Shaanxi Province, China
  • Supported by:
    the Key Project of Shaanxi Province, No. 2018ZDXM-SF-054 (to YZ)

Abstract:

BACKGROUND: More and more studies have shown that miRNA plays an important regulatory role in the pathological development of osteoarthritis.
OBJECTIVE: To review the correlation between miRNA and the pathological development of osteoarthritis.
METHODS: A computer-based search of CNKI and PubMed databases was conducted for the articles concerning miRNA and osteoarthritis published before December 2018. The keywords were “osteoarthritis, miRNA” in Chinese and English, respectively. 
RESULTS AND CONCLUSION: miRNA is closely related to the pathogenesis of osteoarthritis. Abnormal expression of miRNA is involved in chondrocyte proliferation and apoptosis, articular cartilage extracellular matrix homeostasis, chondrocyte inflammation and joint pain in osteoarthritis. Abnormally expressed miRNA can be used as a marker for early diagnosis of osteoarthritis. As a regulatory gene, miRNA has broad prospects in molecular targeted therapy of osteoarthritis.

Key words: osteoarthritis, miRNA, abnormal expression, chondrocytes, extracellular matrix, inflammation, pain, diagnosis, treatment

CLC Number: